Alipogene tiparvovec: Gene therapy for lipoprotein lipase deficiency

Expert Opinion on Biological Therapy

Volumn 13, Issue 1, 2013, Pages 7-10

  Wierzbicki, Anthony S ^a   Viljoen, Adie ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

Author keywords

Alipogene tiparvovec; Chylomicronemia; Gene therapy; Lipoprotein lipase; Triglyceride

Indexed keywords

ALIPOGENE TIPARVOVEC; CHYLOMICRON; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

GENE THERAPY; GENERAL ANESTHESIA; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNOSUPPRESSIVE TREATMENT; PROTEIN EXPRESSION; REVIEW;

DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN LIPASE;

ADENO-ASSOCIATED VIRUS;

EID: 84870874338     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.738663     Document Type: Review

References (21)

1. Viljoen A, Wierzbicki AS. Diagnosis and treatment of severe hypertriglyceridemia. Expert Rev Cardiovasc Ther 2012;10(4):505-14
2. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007;357(10):1009-17
3. Lloret-Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008;37(1):13-12
4. Brunzell JD, Deeb SS. Familial Lipoprotein lipase deficiency, apoC-II deficiency, and hepatic lipase deficiency. In: Pcriver CR, Beaudet AL, Sly WS, et al. editors. The metabolic & molecular bases of Inherited disease. McGraw-Hill; New York: 2001. p. 2789-2816
5. Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 2012;272(2):185-96
6. Brunzell JD. Familial Lipoprotein Lipase Deficiency. Gene Reviews. Available from: Http://www.ncbi.nlm.nih.gov/books/NBK1308/ 2010
7. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 2006;98(4A):27i-33i
8. Wierzbicki AS. Niacin: The only vitamin that reduces cardiovascular events. Int J Clin Pract 2011;65(4):379-85
9. Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002;89(2):229-31
10. Tzotzas T, Krassas GE, Bruckert E. Administration of orlistat in a patient with familial hyperchylomicronemia. Atherosclerosis 2002;165(1):185-6
11. Rader DJ. Gain-of-function mutations and therapeutic implications: Lipoprotein lipase S447X to the rescue. Arterioscler Thromb Vasc Biol 2005;25(10):2018-19
12. Alexander IE, Cunningham SC, Logan GJ, Christodoulou J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther 2008;15(11):831-9
13. Ross CJ, Twisk J, Meulenberg JM, et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum Gene Ther 2004;15(9):906-19
14. Ross CJ, Twisk J, Bakker AC, et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther 2006;17(5):487-99
15. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008;28(12):2303-4
16. Gaudet D, De WJ, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010;11(1):55-60
17. Gaudet D, Methot J, Dery S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL (S447X)) gene therapy for lipoprotein lipase deficiency: An open-label trial. Gene Ther 2012; Epub ahead of print
18. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009;114(10):2077-86
19. Carpentier AC, Frisch F, Labbe SM, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 2012;97(5):1635-44
20. Wierzbicki AS, Hardman T, Prince WT. Future challenges for microsomal transport protein inhibitors. Curr Vasc Pharmacol 2009;7(3):277-86
21. Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: An update. Int J Clin Pract 2012;66(3):270-80